Practice Management News

Over the course of a decade, 54% of drugs and biologics in late-stage trials failed due to poor efficacy or safety concerns, according to findings published in JAMA Internal Medicine.

Hospitals in states that expanded Medicaid experienced reduced uncompensated care costs and increased revenue compared with hospitals in states that did not expand Medicaid, according to data published in JAMA.

Six weeks of Sovaldi with ribavirin produced “sub-optimal” results in patients with hepatitis C, according to research published in Hepatology.

Copay assistance, a seeming resolution to the drug pricing dilemma, is actually the problem, according to a commentary published in Annals of Internal Medicine.

Researchers identified several interventions that resulted in "clinically meaningful reductions" in physician burnout, according to findings published in The Lancet.

The FDA issued a number of important decisions relevant to gastroenterology and hepatology last month, including the approval of a swallowable intragastric balloon for weight loss, two single-use colonoscope systems and two new biologics for Crohn’s disease, one of which is the fourth approved biosimilar in the U.S.

A variety of acute medical conditions typically overseen in a hospital inpatient setting can be managed at lower costs through alternative outpatient strategies that yield similar clinical outcomes and patient satisfaction, according to data published in JAMA Internal Medicine.

A lower number and smaller range of adverse events were reported in published studies compared with those unpublished, according to data published in PLoS Medicine.

Two new American Medical Association analyses support the blocking of the Anthem-Cigna and Aetna-Humana mergers.

From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of today’s physicians and health care executives.